Welcome to our dedicated page for Clearside Biomed news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomed stock.
Clearside Biomedical, Inc. (CLSD) is a biopharmaceutical company that focuses on delivering therapies to the back of the eye through the suprachoroidal space (SCS®). News about CLSD frequently centers on its patented SCS injection platform, its commercial product XIPERE® for uveitic macular edema, and its lead development program CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD).
Investors and observers following CLSD news can expect updates on clinical data from Phase 1/2a and Phase 2b trials of CLS-AX, regulatory interactions such as End-of-Phase 2 meetings and Phase 3 program planning, and preclinical work on small molecule programs targeting geographic atrophy and diabetic macular edema. Company announcements also highlight scientific presentations at major ophthalmology meetings, including ARVO, EURETINA, and other retinal-focused conferences, where Clearside and its collaborators discuss suprachoroidal delivery, trial designs, and platform-related technologies.
Clearside’s news flow also includes developments from its licensing and collaboration partners. These items may cover regulatory approvals and filings for XIPERE or ARCATUS® in various territories, progress in partner-led clinical programs using the SCS Microinjector, and updates on gene therapy or anti-tumor agents delivered via the suprachoroidal route. Corporate and financial updates, such as quarterly results, strategic review announcements, reverse stock split actions, royalty monetization agreements, and Nasdaq listing compliance matters, are also part of the company’s regular disclosures.
More recently, CLSD news has included its decision to explore strategic alternatives for its SCS platform and pipeline, and the subsequent voluntary Chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware with the stated objective of pursuing a sale of substantially all assets. For users tracking CLSD, this news page provides a centralized view of clinical, regulatory, partnership, and restructuring developments affecting the company and its stock.
Clearside Biomedical (Nasdaq: CLSD) filed a voluntary petition under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on November 24, 2025 (Case No. 25-12109) and intends to seek court authorization for a Section 363 auction and sale of its assets. The company says the structured process aims to maximize stakeholder value while normal operations continue under court supervision.
Key assets for sale include the commercial SCS Microinjector platform and XIPERE, the Phase 3-ready CLS-AX program for wet AMD and diabetic retinopathy, IND-ready programs for GA and DME, and rights linked to a royalty sub with a $106.5M revenue cap. Advisors include Cooley, Richards Layton & Finger, and BRG.
Clearside Biomedical (Nasdaq: CLSD) announced multiple presentations featuring its SCS Microinjector® platform at the upcoming 25th EURETINA Congress in Paris from September 4-7, 2025. The presentations will highlight the company's suprachoroidal delivery platform designed for treating various retinal diseases including wet AMD, diabetic retinopathy, and geographic atrophy.
Key presentations include Phase 2b results from the ODYSSEY trial and Phase 3 program updates for CLS-AX in neovascular age-related macular degeneration, presented by Dr. Sobha Sivaprasad. Dr. Victor Chong, Chief Medical Officer, will present a decade-long review of suprachoroidal drug delivery evolution and participate in a panel discussion on geographic atrophy at the Ophthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) has received approval from Health Canada for XIPERE®, a treatment for uveitic macular edema (UME). The drug, which uses Clearside's proprietary SCS Microinjector® for suprachoroidal space delivery, is now approved in multiple global markets including the United States, Canada, Australia, and Singapore.
This regulatory milestone represents continued validation of Clearside's innovative suprachoroidal space injection platform technology. The treatment is currently under regulatory review in China, signaling potential further market expansion.
Clearside Biomedical (Nasdaq: CLSD) announced plans to explore strategic alternatives to advance its proprietary Suprachoroidal Space (SCS®) delivery platform and ophthalmology pipeline. The company has retained Piper Sandler to evaluate options including potential sale, licensing, partnerships, or other strategic transactions.
The company's key assets include their SCS Microinjector®, a proven in-office delivery platform for retinal therapies, and CLS-AX, their Phase 3-ready wet AMD treatment that achieved positive Phase 2b results. Due to challenging market conditions, Clearside will transition all employees to consulting roles and pause internal R&D programs during the strategic review.
Clearside has established five commercial and late-stage development licensing collaborations with partners including Aura Biosciences, Bausch + Lomb, BioCryst, REGENXBIO/AbbVie, and Arctic Vision/Santen.
Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will engage in a fireside chat on Tuesday, May 27, 2025, at 9:00 a.m. ET. Investors and interested parties can access the live and archived webcast through the Events and Presentations section of Clearside's website. The webcast recording will remain available for three months after the event.
- Development of the first machine learning algorithm for imaging suprachoroidal space (SCS) drug delivery
- Creation of a novel force analysis method for drug-device optimization
- Over 15,000 completed injections in their clinically validated training program
- Successful Phase 2b results supporting CLS-AX as a potential safe and long-acting therapy
Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, after market close. The company has noted that it will not hold a conference call this quarter. Investors can access quarterly results and other investor-related information through the Investors section of Clearside's website.
Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Citizens Life Sciences Conference. The company's management will engage in a fireside chat on May 7, 2025, at 1:00 p.m. ET. Investors can access the live and archived webcast through Clearside's website under the Investors section: Events and Presentations. The webcast recording will remain available for three months after the event.